| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-221
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-221 |
| filingDate |
2011-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf9a9d1df98cdf4a75e7235423510eed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4a44b25d0bfa16ebd334225b41d193f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_670695a3849aeefaaddece893eabe430
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a141d54fe9389426a84f24326bb80d6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e3b00e67ebe40d86f74dc5394ac7acc |
| publicationDate |
2015-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2564941-C2 |
| titleOfInvention |
Treatment of hypertension and/or prevention and treatment of heart failure in mammal, receiving anticoagulant therapy |
| abstract |
FIELD: medicine. n SUBSTANCE: to treat heart failure in individual, receiving anticoagulant therapy introduced are: a) pharmaceutical composition, including therapeutically effective quantity of trisodium [3-((1S,3R)-1-diphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl-{2″-(tetrazol-5-ylate)diphenyl-4′-ylmethyl}amino)butirate]semi-pentahydrate and pharmaceutically acceptable carrier or b) pharmaceutical composition, including therapeutically effective quantity of (i) valsartan or its pharmaceutically acceptable salt; (ii) ethyl ester of N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid or 2R,4S)-5-diphenyl-4-yl-4-(3-carboxypropyonylamino)2-methylpentanoic acid or its pharmaceutically acceptable salt; and (iii) pharmaceutically acceptable carrier. n EFFECT: method makes it possible to increase treatment efficiency with absence of pharmacokinetic or pharmacodynamic interaction with warfarin. n 6 cl, 4 dwg, 3 tbl |
| priorityDate |
2010-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |